Biogen and Eisai announced a positive surprise for a closely-watched Alzheimer's drug candidate in a late-stage study.

A surprise move to stem soaring bond yields by the Bank of England has U.S. stocks ending higher Wednesday.

“Today’s announcement gives patients and their families hope that lecanemab, if approved, can potentially slow the progression of Alzheimer’s disease," said Biogen CEO Michel Vounatsos.

Stock futures resume slump on rate hike, recession concerns; Apple shares slide on report of waning iPhone demand; Biogen shares soar after positive results from Alzheimer's trial; Elon musk seeks to overturn sec rule on Twitter vetting and Hurricane Ian to slam Florida coast as category 4 storm.

The whistleblower provision has been around for a long time but it still has plenty of bite.

Biotech stocks remain undervalued, but investors could start building a position.

Another controversial neuroscience drug could soon be approved.

The Alzheimer’s Drug Discovery Foundation has doubled contributions to raise a stunning $100M for badly-needed research.

Stocks finish higher Tuesday as the Federal Reserve begins its two-day policy meeting amid bets on faster and deeper near-term rate hikes.

Universal Studios has begun construction on Epic Universe, its third theme park planned for Florida.

The e-commerce giant has just made a decision that suggests the health of the economy is not improving.

Solar stocks like Enphase Energy and First Solar are getting hit hard. Here's how to trade them from here.